Many studies have shown that short sleep duration and/or poor sleep quality is associated with increasing rates of cardiovascular (CVD) mortality and morbidity. One hypothesized explanation for this association has been that sleep loss is a type of chronic stress that induces dysregulation of biological systems that ultimately increase the risk of CVD. One biological system that has been thought to link sleep loss and CVD is the hypothalamus-pituitary-adrenal (HPA) axis. A number of studies using small or convenience samples have addressed the effects of sleep deprivation on cortisol. Only a few studies have examined the association of habitual short sleep duration and/or poor sleep quality with changes in the diurnal cortisol in population based-samples; those studies vary in their methodology and in findings. Another biological system that has been thought to link sleep loss and CVD is the autonomic nervous system (ANS), through overactivation of the sympathetic nervous system (SNS) and/or probably a withdrawal of the parasympathetic nervous system. Experimental studies have shown an association between the sleep stages and markers of the sympathetic system. However, very few studies of habitual sleep duration/sleep quality and ANS markers have been conducted. Even fewer studies have examined the association of habitual sleep duration and/or sleep quality and ANS responses to a stress challenge in a population-based sample. The findings again have been inconsistent probably due to the use of different methodology and different samples. This dissertation used measures of salivary diurnal cortisol as well as cortisol responses to a stress challenge protocol to assess the relationship of habitual sleep duration and/or sleep quality with diurnal cortisol profile in natural conditions and in response to a stress challenge protocol in a laboratory setting. Diurnal cortisol was assessed from up to 16 samples of salivary cortisol for two days. Cortisol responses to a stress challenge were assessed from four salivary samples taken during the stress challenge that was performed in a different day than the diurnal cortisol collection. To examine the relationship of habitual sleep duration and/or sleep quality and markers of the ANS, this dissertation used continuous cardiovascular measures (heart rate and heart rate variability) and four salivary amylase samples obtained during the stress challenge. The stress challenge included mental stress and orthostatic stress. Sleep duration and sleep efficiency (an objective measure of sleep quality) were assessed from 7-day actigraphy and sleep diaries. Insomnia symptoms (a subjective measure of sleep quality) were also assessed using a questionnaire that included the Women’s Health Initiative Insomnia rating scale (WHIIRS). We used mixed models so as to account for the repeated measures of diurnal salivary cortisol levels as well as the responses (reactivity and recovery) to the stress challenge tests. Chapter 1 presents an introduction to this dissertation discussing the relationship between short sleep duration and/or poor sleep quality and CVD morbidity and mortality. Chapter 2 presents a systematic literature review of studies of the association between habitual sleep duration and/or sleep efficiency and markers of neuro-endocrine systems: HPA and ANS. These are plausible mechanisms that link short and/or poor sleep to CVD morbidity and mortality. Chapter 3 presents our analyses of the relationship between short sleep duration and/or poor sleep quality and features of the diurnal cortisol. We hypothesized that those participants whose slept < 6 hours per night or whose sleep efficiency was < 85% would have higher cortisol levels on awakening, flatter cortisol awakening responses (CAR), and higher evening cortisol levels than participants who slept longer or slept better. We found that short sleepers had higher evening cortisol than the longer sleepers and that this association persisted after the adjustment for several known confounders. In chapter 4, we examined how the same groups of participants responded in terms of hormones (cortisol and amylase) and cardiovascular indices (heart rate (HR) and HR variability (HRV)) to a stress challenge test. We hypothesized that those participants who slept for a shorter time or whose sleep was of poorer quality would have more exaggerated responses to and less recovery from a stress challenge test than participants who slept longer or slept better. We found that participants with insomnia had exaggerated high frequency-HRV (HF-HRV) orthostatic reactivity. In an extended analysis, we found that participants who slept less than 7 hours/night had exaggerated heart rate reactivity to a mental stress test compared to participants who slept 7 or more hours/night, but this association was attenuated after adjustment for naps. Paradoxically, we also found that participants who slept less than 7 hours had higher HF-HRV recovery from mental stress compared to longer sleepers (≥7 hours). Short sleep duration or low sleep efficiency was not associated with cortisol or amylase responses to the stress challenge protocol. These findings suggest that sustained high evening cortisol levels and cardiovascular responses to a stress challenge may be among the mechanisms linking short/poor sleep and CV disease.

Thesis (Ph. D.)--Ohio State University, 2006. / Available online via OhioLINK's ETD Center; full text release delayed at author's request until 2009 May 24

BACKGROUND: Obesity is a leading health burden of the 21st century. Alterations of the individual endocrine stress response and the monoamine system may pathophysiologically contribute to the obesity pandemic and its metabolic and mental complications. OBJECTIVES: (i) to measure hypothalamic-pituitary-adrenal (HPA) axis responsiveness and its relation to serum concentrations of the arginine-vasopressin (AVP) surrogate copeptin in subjects with obesity (OB) compared to non-obesity controls (NOC), (ii) to test whether HPA axis responsiveness and copeptin are related to central noradrenaline (NA) transporter (NAT) availability, (iii) to assess brain serotonin transporter (SERT) binding potentials in OB compared to NOC. METHODS: 40 subjects with obesity (BMI > 35kg/m2) were compared to 25 non-obesity controls, matched for age and sex. (i) All individuals underwent the combined dexamethasone/corticotropin releasing hormone (dex/CRH) test. Plasma ACTH and cortisol curve parameters were derived, and copeptin was assessed in the 1500h sample. (ii) Positron emission tomography (PET) was applied in 10 OB and 10 NOC using the NAT-selective radiotracer S,S-[11C]O-methylreboxetine (MRB) and associated to curve indicators derived from the dex/CRH test as well as to copeptin. (iii) PET using the SERT selective radiotracer [11C] DASB was performed in 30 OB and 15 NOC for intergroup comparison. RESULTS: (i) OB subjects showed an increased HPA axis responsiveness as measured by cortisol concentrations after CRH stimulation. Correspondingly, the AVP surrogate copeptin was higher in OB along with being significantly associated to HPA axis reactivity. OB subjects had a higher adrenal sensitivity as measured by a lower ACTH/cortisol ratio. (ii) In NOC, the HPA response was related to NAT availability of the amygdala and the orbitofrontal cortex while in OB, this association was located in the hypothalamus. (iii) There were no differences in SERT availability between OB and NOC, but a higher inter-regional SERT connectivity was observed in OB. CONCLUSION: This work supports the notion of an increased endocrine stress response in human obesity, pointing to interacting alterations of the HPA and neurohypophyseal axes. Normally, these stress axes seem to be linked to prefrontal-limbic NA signaling, whereas a loss of this association in favor of a hypothalamic-centered relation is observed in OB. The SERT network pattern is more closely inter-related in OB, albeit central SERT concentrations per se do not differ between OB and NOC.:ABBREVIATIONS 4 LIST OF FIGURES 5 I. BIBLIOGRAPHIC DESCRIPTION 6 II. INTRODUCTION 7 2.1 Obesity as a global health burden 7 2.2 Neurobiology of stress 8 2.3 Stress and obesity 8 2.4 Neuroendocrine correlates of the stress response – The hypothalamic pituitary-adrenaland neurohypophyseal axes 9 2.4.1 Anatomy of the hypothalamic-pituitary-adrenal and neurohypophyseal axes 10 2.4.2 The role of CRH, ACTH and cortisol in the context of metabolism and obesity 11 2.4.3 The role of AVP in the context of metabolism and obesity 12 2.4.4 Measuring HPA axis responsiveness by means of the combined dexamethasonecorticotropin-releasing hormone (dex/CRH) test 12 2.4.5 Measuring AVP secretion by its equally-released surrogate copeptin 14 2.5 The noradrenergic system in the context of obesity and stress axis modulation 14 2.5.1 NA and its influence on feeding behavior16 2.5.2 The association of the noradrenergic system with the HPA and neurohypophyseal axes 16 2.5.3 Monoamine transporters as regulators of neurotransmitter signaling 17 2.5.4 Noradrenaline transporter imaging 18 2.6 The serotonergic system in obesity 19 2.6.1 Role of serotonin in the context of feeding behavior and metabolism 20 2.6.3 5-HTT imaging 21 2.7 Objectives and hypotheses 22 2.8 Study design 23 III. RESULTS 24 3. 1 Post-dexamethasone serum copeptin corresponds to HPA axis responsiveness in human obesity 24 3. 2 Central noradrenaline transporter availability is linked with HPA axis responsiveness and copeptin in human obesity and non-obese controls 34 3. 3 Central serotonin transporter availability in highly obese individuals compared with nonobese controls: A [11C] DASB positron emission tomography study 46 IV. SUMMARY 56 4.1 Subjects with obesity show an enhanced HPA axis responsiveness which correlates to serum concentrations of the AVP surrogate copeptin and abdominal fat distribution 56 4.2 HPA axis responsiveness and copeptin concentrations are differentially related to central NAT availability in subjects with obesity compared to non-obesity controls 58 4.3 Central serotonin transporter availability does not significantly differ in subjects with obesity compared to their non-obesity counterparts 59 4.4 Future direction 61 V. References 62 VI. APPENDICES 79 6.1 Curriculum vitae 79 6.2 Publications 81 6.3 Scientific contribution of the doctoral candidate to the publications 82 6.4 Declaration of the independent writing of this thesis 83 6.5 Acknowledgements 84

Posttraumatic stress disorder (PTSD) is a trauma-related disorder that may develop in response to traumatic or stressful events. Dysfunction of the Hypothalamic-Pituitary-Adrenal (HPA) axis has been implicated in the disorder. Studies support such dysfunction as being a consequence of PTSD, rather than a precursor. However, most studies of the HPA are either cross-sectional or have been carried out in adults. The aim of the present study was to identify whether HPA dysregulation interacts with stressful experiences to increase the likelihood of developing PTSD symptoms in a community-recruited sample of healthy adolescent girls. Adolescent girls (N = 550) and one of their parents participated. Adolescents’ clinical symptoms were assessed at baseline and at a nine month follow-up. Saliva samples were collected from all adolescent participants at waking, 30 minutes after waking, and 8 pm on 3 consecutive days. Flattened diurnal slope of cortisol at baseline was associated with increased PTSD symptoms nine months later. Baseline cortisol awakening response (CAR) per se was not prospectively related to developing PTSD symptoms, but its interactions with stressful experience was associated with elevated PTSD symptoms at follow-up. Effects were small and need to be replicated in samples with more severe stressors, as well as more clinical levels of PTSD. Nevertheless, findings suggest that dysregulated basal HPA functioning may be involved in the development of PTSD symptoms.

There is now considerable evidence that both schizophrenia and affective disorders have their origin at least in part in events that occur during early pre- and post-natal development. In the case of schizophrenia, many observations, for example, increased risk for schizophrenia in the offspring of mothers who had influenza A during their second trimester of pregnancy and evidence for abnormal neuronal migration in the cerebral cortex of post mortem tissue from schizophrenic patients, suggest that a second trimester insult may have occurred and that this insult may have increased the risk for the development of schizophrenia in late adolescence or early adulthood. Animal studies have found that rats that undergo excitotxic damage to the ventral hippocampus on postnatal day 7 develop exaggerated sensitivity to dopamine-stimulating drugs or to stressful stimuli that becomes apparent after sexual maturity but not before, providing a neurodevelopmental model of schizophrenia. Similarly, post-weaning social isolation leads to nehanced responses to dopaminergic drgus and to stress that emerges after sexual maturity. These animal models are proving to be valuable tools to study the neurobiological mechanisms mediating the influence of early insults to the nervous system on later behavioural functins. In the case of affective disorders, although the evidence is not as strong, a number of the same observations have been made suggesting that an insult during early ontogeny may lead to the development of affective disorders later in life. For example, retrospective studies of people with affective disorders showed that they were more likely to have attained motor milestones at a later age and to have had poorer academic performance as children. There is a wealth of evidence suggesting hyperfunctioning of the hypothalamic-pituitary-adrenal (HPA) axis in affective disorders. Animal studies have shown that early matenal deprivation can lead to lasting changes in the reactivity of the HPA axis to stressful stimuli, providing another link from early experience to adult psychopathology. Continued studies of the effects of pre- and early post-natal events on the development of the nervous system and the relationships of these events to schizophrenia or affective disorder will provide new insights into the mechanisms underlying these common neuropsychiatric illnesses.

Thesis (MSc (Physiological Sciences))--University of Stellenbosch, 2006. / Early adverse life events appear to increase the susceptibility of developing psychiatric disorders later in life. The molecular mechanisms involved in the development of pathological behaviour remain unclear. Dysregulation of the hypothalamic-pituitary-adrenal axis and alterations in neurotrophic factors have been implicated.

Glucocorticoid hormones modulate acute and chronic behavioral and molecular responses to drugs of abuse including psychostimulants and opioids. Acute ethanol activates the hypothalamic pituitary adrenal (HPA) axis causing the release of adrenal glucocorticoid hormones, but following chronic ethanol the HPA axis is dysregulated in both humans and rodents. Thus, there is growing evidence that glucocorticoids might also modulate behavioral and molecular responses to ethanol. Previous microarray studies in the Miles’ laboratory have shown that the well-known glucocorticoid responsive gene, Serum and Glucocorticoid-regulated Kinase 1, Sgk1, is prominently up regulated by acute ethanol (2 g/kg) in the prefrontal cortex (PFC) of DBA/2J mice. Functionally, Sgk1 is an important focal point of intracellular signaling cross-talk through which the cell surface receptors, nuclear receptors, and cellular stress pathways converge to control many cellular processes including receptor or ion channel trafficking, cell proliferation and/or apoptotic responses. In the aforementioned microarray studies, Sgk1 was accompanied by a highly correlated group of genes, many of which are also known to respond to glucocorticoids. This suggests that stress-related signaling events might play an important role in ethanol regulation of the Sgk1 gene network. Prior work by others showed that Sgk1 plays an important role modulating synaptic plasticity occurring in memory. Based on these findings, it is hypothesized that glucocorticoids and glucocorticoid responsive genes are responsible for modulating acute and chronic cellular and behavioral responses to ethanol including locomotor activation and ethanol sensitization. In particular, because Sgk1 is regulated by ethanol, has a well-established role in learning and memory and is responsive to glucocorticoid signaling we hypothesize that Sgk1 is involved in modulating acute and chronic cellular and behavioral responses to ethanol including ethanol sensitization. Our results indicate that the induction of glucocorticoid responsive genes may play a role in regulating acute behavioral and cellular responses to ethanol. Adrenalectomized (ADX) and mifepristone (RU-486) both impaired acute ethanol (2 g/kg) induced locomotor activation in DBA/2J mice without affecting basal locomotor activity. ADX mice showed microarray gene expression changes in the PFC that significantly overlapped with acute ethanol-responsive gene sets derived by our prior microarray studies. Additionally, acute ethanol regulates Sgk1 transcription via glucocorticoid receptor binding to the Sgk1 promoter. Furthermore, increases in Sgk1 may occur to compensate for decreases in SGK1 protein and phosphorylation of SGK1 and its well-known target N-myc downstream-regulated gene 1 (NDRG1) is significantly increased 15 minutes following ethanol administration. Finally, Sgk1 intensifies and prolongs the expression phase of sensitization in D2 mice. Our studies suggest that ethanol’s activation of adrenal glucocorticoid release and subsequent glucocorticoid receptor activation may partially modulate ethanol’s acute locomotor activation in male D2 mice. Furthermore, adrenal glucocorticoid basal tone regulates PFC gene expression. A significant set of acute ethanol-responsive genes are regulated by adrenal glucocorticoid basal tone suggesting that glucocorticoid regulated PFC gene expression may be an important factor modulating acute behavioral responses to ethanol. Sgk1 is acutely regulated following ethanol administration by the glucocorticoid receptor binding to the Sgk1 promoter. Altogether, these results suggest a critical role for the hypothalamic pituitary adrenal axis and Sgk1 in regulating the acute and chronic cellular and behavioral responses to ethanol.

Introdução: Diversos estudos sugerem que o estresse nas fases iniciais de desenvolvimento pode induzir alterações persistentes na capacidade do eixo Hipotálamo-Pituitária-Adrenal (HPA) em responder ao estresse na vida adulta. O desequilíbrio do cortisol tem sido identificado como um correlato biológico dos transtornos depressivos. Essas anormalidades parecem estar relacionadas às mudanças na capacidade dos glicocorticóides circulantes em exercer seu feedback negativo na secreção dos hormônios do eixo HPA por meio da ligação aos receptores mineralocorticóides (RM) e glicocorticóides (RG) nos tecidos do eixo HPA. Devido à grande variedade de estressores, assim como os diferentes subtipos de depressão, os achados dos estudos atuais têm sido inconsistentes. Dessa forma, necessitando de mais estudos para que se possa elucidar os mecanismos envolvidos na associação entre o Estresse Precoce (EP) e o desenvolvimento de quadros depressivos. Objetivo: O objetivo deste estudo é avaliar a correlação entre Estresse Precoce e alterações no eixo Hipotálamo-Pituitária-Adrenal e na função dos receptores glicocorticóides e mineralocorticóides em pacientes depressivos. Metodologia: Foram recrutados inicialmente 30 sujeitos divididos em dois grupos: grupo de pacientes com diagnóstico de episódio depressivo atual (n=20) e grupo de controles (n=10). Posteriormente os pacientes foram divididos em outros dois grupos de acordo com o EP, compondo a amostra final por três grupos: grupo de pacientes depressivos com presença de EP (n=13), grupo de pacientes depressivos com ausência de EP (n=7) e grupo de controles (n=10). Os pacientes foram avaliados por meio de Entrevista Clínica de acordo com os critérios diagnósticos do DSM-IV, para a confirmação do diagnóstico. Para avaliação da gravidade dos sintomas depressivos foi aplicada a Escala de Depressão de Hamilton (HAM-D21), sendo incluídos apenas pacientes com HAM-D21 17. A presença de EP foi confirmada através da aplicação do Questionário Sobre Traumas na Infância (QUESI). Foram utilizados também a Escala de Avaliação de Depressão de Montgomery-Asberg (MADRS), o Inventário de Depressão de Beck (BDI), o Inventário de Ansiedade de Beck (BAI), a Escala de Ideação Suicida de Beck (BSI), a Escala de Desesperança de Beck (BHS), a Escala Hospitalar de Ansiedade e Depressão (HAD) e a Escala de Impulsividade de Barratt (BIS-11) para a avaliação de sintomas psiquiátricos. A avaliação endócrina foi controlada por placebo, cego por parte dos controles e pacientes, não randomizado, com desenho de medidas repetidas, onde os efeitos da Fludrocortisona (0.5 mg) e da Dexametasona (0.5 mg) foram avaliados através do cortisol salivar e plasmático. A secreção de cortisol plasmático e salivar foi avaliada nos sujeitos, após a administração de uma cápsula de Placebo, Fludrocortisona e Dexametasona às 22hs do dia anterior. O cortisol salivar foi coletado às 22h, ao acordar, 30 e 60 minutos após acordar e antes da coleta plasmática, nos dias seguintes após os desafios. Resultados: Na amostra de pacientes depressivos e controles, encontramos níveis significativamente menores de cortisol salivar ao acordar após a administração de Placebo nos pacientes depressivos comparados aos controles. Encontramos também uma tendência dos pacientes apresentarem níveis maiores de cortisol salivar ao acordar do que os controles após a administração de Dexametasona. Quando avaliado o cortisol após a administração de Fludrocortisona, os pacientes apresentaram níveis significativamente menores de cortisol salivar 30 minutos após acordar e na Área Sob a Curva (AUC) do que os controles. Além disso, encontramos também uma tendência dos pacientes depressivos apresentarem níveis menores de cortisol salivar 60 minutos após acordar do que os controles. Quando comparados entre pacientes depressivos com presença e ausência de EP e controles, encontramos uma tendência dos pacientes depressivos com ausência de EP apresentarem níveis menores de cortisol salivar ao acordar após Placebo do que os controles. As médias dos níveis de cortisol salivar ao acordar não diferiram entre os pacientes com presença de EP e os controles e entre os pacientes do grupo presença e ausência de EP. Com relação aos níveis de cortisol salivar após a administração de Dexametasona entre pacientes depressivos com presença e ausência de EP e controles, os pacientes depressivos com ausência de EP apresentaram níveis significativamente maiores de cortisol salivar ao acordar do que os controles. Encontramos também uma tendência dos pacientes com ausência de EP apresentarem níveis maiores de cortisol salivar ao acordar do que os pacientes com presença de EP, porém não foram encontradas diferenças significativas entre os pacientes com presença de EP e os controles. Conclusão: Nossos dados demonstram uma hipoatividade do eixo HPA nos pacientes depressivos. Além disso, estes achados sugerem que esta desregulação do eixo HPA se deva em parte a uma diminuição da sensibilidade dos RG e uma hiperativação dos RM nos pacientes depressivos. No entanto, quando comparados pacientes depressivos com presença e ausência de Estresse Precoce, os desafios com agonistas seletivos como a Dexametasona (agonista RG) e a Fludrocortisona (agonista RM) não foram capazes de detectar esta diferença fisiopatológica e distinguir entre os diferentes tipos de psicopatologia. Dessa forma, estes resultados sugerem que estudos com um agonista misto (RG/RM) como a Prednisolona teriam potencial para distinguir os pacientes depressivos com presença de Estresse Precoce. / Introduction: Several studies suggest that stress in early stages of development can induce persistent changes in the ability of the Hypothalamic-Pituitary-Adrenal (HPA) axis to respond to stress in adulthood. The imbalance of cortisol has been identified as a biological correlate of depressive disorders. These abnormalities seem to be related to changes in the ability of circulating glucocorticoids to practice their negative feedback on the secretion of HPA axis hormones through connecting to the mineralocorticoid receptor (MR) and glucocorticoid (GR) in the tissues of HPA axis. Due to the wide variety of stressors, as well as the different subtypes of depression, the findings of current studies have been inconsistent. Thus, more studies need to be able to elucidate the mechanisms involved in the association between Early Life Stress (ELS) and the development of depression. Objective: The objective this study is to evaluate the correlation between of Early Life Stress and changes in Hypothalamic-Pituitary-Adrenal axis and at receptors function glucocorticoid and mineralocorticoid in depressive patients. Methodology: We recruited 30 subjects initially divided into two groups: patients with current depressive episode (n =20) and control group (n = 10) Subsequently, patients were divided into two groups according to the ELS, making the final sample of three groups: depressive patients with ELS (n =13) group of depressive patients without ELS (n=7) and control group (n=10). Patients were evaluated by clinical interview according to the diagnostic criteria of DSM-IV to confirm the diagnosis. To evaluate the severity of depressive symptoms was applied to the Hamilton Depression Scale (HAM-D21), and included only patients with HAM-D21 17. The presence of ELS was confirmed by the Childhood Trauma Questionnaire (CTQ). We also used the Depression Rating Scale Montgomery-Asberg (MADRS), the Beck Depression Inventory (BDI), the Beck Anxiety Inventory (BAI), the Scale for Suicide Ideation Beck (BSI), the Scale Beck Hopelessness (BHS), the Hospital Anxiety and Depression Scale (HADS) and the Barratt Impulsiveness Scale (BIS-11) for the assessment of severity psychiatric symptoms. Endocrine evaluation was placebo-controlled, blinded by the patients and controls, non-randomized design with repeated measures, where the effects of Fludrocortisone (0.5 mg) and dexamethasone (0.5 mg) were assessed using salivary cortisol and plasma. The secretion of plasma cortisol and salivary was evaluated in the subjects, after administration of a capsule of Placebo, Fludrocortisone and Dexamethasone to 22hs the previous day. The salivary cortisol was collected at 22h, on waking, 30 and 60 minutes after waking and before plasma collection in the following days after the challenges. Results: In these sample of depressed patients and controls, we found significantly lower levels of salivary cortisol around waking after administration of Placebo in depressed patients than controls. We also found a trend for patients to have higher levels of salivary cortisol than controls on awakening after administration of Dexamethasone. When measured cortisol after administration of Fludrocortisone, patients showed significantly lower levels of salivary cortisol 30 minutes after waking and the Area Under the Curve (AUC) than controls. In addition, we also found a tendency for depressed patients showed lower levels of salivary cortisol 60 minutes after awakening than controls. When compared between depressed patients with and without ELS and controls, we found a tendency for depressed patients without ELS presented lower levels of salivary cortisol on awakening after Placebo than controls. The mean salivary cortisol levels on waking did not differ between patients with ELS and controls and between patients with and without ELS. The levels of salivary cortisol after Dexamethasone administration between depressed patients with and without ELS and controls, depressed patients without ELS had significantly higher levels of salivary cortisol on awakening than controls. We also found a trend for patients without Early Life Stress have higher levels of salivary cortisol upon waking than patients with Early Life Stress, but there were no significant differences between patients with Early Life Stress and controls. Conclusion: Our data show a hypoactivity of the HPA axis in depressed patients. Moreover, these findings suggest that this dysregulation HPA axis is partly due to a decrease the sensitivity of RG and a hyperactivation of MR in patients depressive. However, when compared depressed patients with and without Early Life Stress, the challenges with selective agonists as the Dexamethasone (agonist GR) and Fludrocortisone (agonist MR) were not able to detect this difference pathophysiological and distinguish between the different types of psychopathology. Thus, these results suggest that studies with a mixed agonist (GR/MR) such as Prednisolone have potential to distinguish of depressive patients with Early Life Stress.

Introdução: Crescentes evidências indicam que o abandono e o abuso infantis são fatores de risco para transtornos psiquiátricos. Estudos realizados tanto em animais como em humanos sugerem que o estresse nas fases iniciais de desenvolvimento pode induzir alterações persistentes na capacidade do eixo HPA em responder ao estresse na vida adulta e que esse mecanismo pode levar a uma maior suscetibilidade à depressão. Esta desregulação do eixo HPA parece estar relacionada às mudanças na capacidade dos glicocorticóides circulantes em exercer seu feedback negativo na secreção dos hormônios do eixo HPA por meio da ligação aos receptores de mineralocorticóides (MR) e glicocorticóides (GR) nos tecidos do eixo HPA. Objetivo: O objetivo deste trabalho foi avaliar a resposta do eixo HPA frente aos agonistas e antagonistas dos GR e MR em pacientes depressivos com e sem estresse precoce (EP) e controles. Metodologia: Selecionamos uma amostra total de 75 sujeitos composta por um grupo de pacientes com diagnóstico de episódio depressivo atual (n=47) e um grupo de controles saudáveis (n=28). Os pacientes foram divididos em 2 grupos de acordo com o estresse precoce: um grupo de pacientes depressivos com EP (n=33) e um grupo de pacientes depressivos sem estresse precoce (n=14). Os pacientes foram avaliados por meio da Mini Entrevista Neuropsiquiátrica Internacional (MINI-Plus), para a confirmação do diagnóstico. Para avaliação da gravidade dos sintomas depressivos foi aplicada a Escala de Depressão GRID de Hamilton (GRID-HAM-D21), sendo incluídos apenas pacientes com HAM-D21>=16. Para a avaliação do estresse precoce foi aplicado o Questionário Sobre Traumas na Infância (CTQ). Utilizamos também a Escala de Avaliação de Depressão de Montgomery-Asberg (MADRS), o Inventário de Depressão de Beck (BDI-II), o Inventário de Ansiedade de Beck (BAI), a Escala de Desesperança de Beck (BHS), a Escala de Ideação Suicida de Beck (BSI), a Escala de Impulsividade de Barratt (BIS-11) e o Questionário de Qualidade de Sono de Pittsburg (PSQI), para a avaliação dos sintomas psiquiátricos. A avaliação endócrina foi controlada por placebo, cego por parte dos controles e pacientes, não randomizada, onde os efeitos da fludrocortisona (0.5 mg), da prednisolona (5 mg), da dexametasona (0.5 mg) e da espironolactona (400mg) foram avaliados através do hormônio adrenocorticotrópico (ACTH) plasmático, do cortisol plasmático e salivar, da prolactina plasmática e do sulfato de desidroepiandrosterona (DHEA-S) plasmático. A secreção de cortisol salivar e dos hormônios plasmáticos foi avaliada em todos os sujeitos, após terem tomado no dia anterior às 22h: uma cápsula de placebo, fludrocortisona, prednisolona, dexametasona e espironolactona. A secreção de cortisol salivar foi avaliada às 22h após a tomada da medicação ou do placebo, ao acordar, 30 e 60 min após acordar e às 9h (antes da coleta plasmática), para avaliação da resposta do cortisol ao acordar (CAR) e do ritmo circadiano do cortisol (RC). Foi realizado também uma coleta plasmática as 9h nos dias seguintes após os desafios para medir o cortisol plasmático, o ACTH, o DHEA-S e a prolactina. Resultados: Os pacientes depressivos apresentaram níveis basais menores de cortisol salivar, de prolactina e de DHEA-S e níveis maiores na relação cortisol/DHEA-S. Não foram encontradas diferenças entre os pacientes depressivos e os controles nos níveis basais de ACTH, de cortisol plasmático, na CAR e no RC. Os pacientes depressivos apresentaram níveis menores de ACTH e de DHEA-S após a dexametasona e a fludrocortisona e tenderam a apresentar níveis menores de cortisol salivar após a fludrocortisona. Após a espironolactona encontramos níveis menores de ACTH, de cortisol salivar e de DHEA-S e níveis maiores no índice cortisol/DHEA-S nos pacientes depressivos. Os pacientes depressivos apresentaram também níveis menores de DHEA-S após a prednisolona, porém não foram encontradas diferenças entre os grupos nos demais hormônios avaliados após a prednisolona. Não foram encontradas diferenças no cortisol plasmático e na prolactina após os desafios entre os pacientes depressivos e os controles. Com relação à avaliação do estresse precoce nas medidas hormonais, encontramos uma tendência dos pacientes com EP apresentarem níveis menores basais de prolactina e após a fludrocortisona, a prednisolona, a dexametasona e a espironolactona do que os pacientes sem EP. No entanto, não foram encontradas diferenças entre os grupos nas demais medidas hormonais basais e após os desafios avaliadas neste estudo. Conclusão: Nossos achados fornecem evidências de que existem diversas alterações nas medidas hormonais relacionadas ao funcionamento do eixo HPA e de seus receptores GR e MR nos pacientes depressivos, associado à hipocortisolemia e um aumento do feedback inibitório mediado pelos GR e MR. Sugerem também o envolvimento da prolactina no desenvolvimento de quadros depressivos com estresse precoce, porém mais estudos são necessários para elucidarmos melhor a importância dos demais hormônios do eixo HPA e dos seus receptores em quadros depressivos com estresse precoce / Introduction: There are evidences indicating that child neglect and abuse are risk factors for psychiatric disorders. Studies that had as subjects animals or human suggest that stress in early phases of development may induce persistent changes in HPA axis response to stress in adulthood, which can lead to a greater susceptibility of developing depression. These abnormalities appear to be related to changes in the ability of circulating glucocorticoids and negative feedback on the secretion of HPA hormones through binding to glucocorticoid (GR) and mineralocorticoid receptors (MR) in HPA tissue. Aim: The aim of the present study was to assess HPA response after ingestion of GR and MR agonists and antagonists by depressive patients with and without early life stress (ELS) and controls. Methods: The sample was composed by a group of patients in current depressive episode (n=47), and a healthy control group (n=28). The depressed patients were divided in 2 groups, according to the presence or absence of ELS - a group with ELS (n=33) and a group without ELS (n=14). For diagnostic assessment, MINI International Neuropsychiatric Interview (MINI-Plus) was used. To assess the intensity of depressive symptoms, GRID-Hamilton Depression Rating Scale (GRIDHAM-D21) was applied, and for being included in the patient\'s group, subjects had to score >=16 in GRID-HAM-D21. To assess ELS, Childhood Trauma Questionnaire (CTQ) was applied. Other instruments were also used in the present study to assess psychiatric symptoms: Montgomery-Åsberg Depression Rating Scale (MADRS), Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory, Beck Hopelessness Scale (BHS), Beck Scale for Suicide (BSI), Barratt Impulsiveness Scale (BIS-11), and Pittsburg Sleep Quality Index (PSQI). The neuroendocrine assessment was controlled using placebo, blind to subjects, and non-randomized. The effects of fludrocortisone (0.5 mg), prednisolone (5 mg), dexamethasone (0.5 mg), and spironolactone (400mg) were assessed by measuring plasmatic adrenocorticotropic hormone (ACTH), plasmatic and salivary cortisol, plasmatic prolactin, and plasmatic dehydroepiandrosterone sulfate (DHEA-S). The secretion of all plasmatic hormones was assessed in all subjects in blood collection sample at 9AM, after they took a pill containg placebo or fludrocortisone or prednisolone or dexamethasone or spironolactone, the day before, at 10 PM. The secretion of salivary cortisol assessed the day before 10 PM (after the ingestion of the pill), upon awakening, 30 minutes and 60 minutes after awakening, and at 9AM (before plasmatic collection), for assessed the cortisol awakening response (CAR) and the cortisol circadian rhythm (CR). At 9 AM there was a blood sample collection to assess plasmatic cortisol, ACTH, DHEA-S and prolactin. Results: Depressive patients presented lower basal levels of salivar cortisol, plasmatic prolactin and DHEA-S, and higher levels in the ratio cortisol/DHEA-S. There were no differences between depressive patients and healthy controls in basal levels of ACTH, plasmatic cortisol, in CAR, and in CR. Depressive patients had lower levels of ACTH and DHEA-S after dexamethasone and fludrocortisone, and there was a tendency of having lower salivary cortisol levels after fludrocortisone. After spironolactone, lower levels of ACTH, salivary cortisol, DHEA-S were found, and higher levels in ratio cortisol/DHEA-S were found in depressive patients. These patients also presented lower levels of DHEA-S after prednisolone, although there were no differences between groups concerning the levels of other hormones assessed after prednisolone. There were no differences found in plasmatic cortisol and prolactin levels after all challenges between depressive patients and controls. Considering ELS and hormonal level assessment, there was a tendency of patients with ELS of presenting lower levels of prolactin after placebo, fludrocortisone, prednisolone, dexamethasone, and spironolactone than patients without ELS. Nevertheless, there were no differences between these groups concerning the other hormonal basal levels and after the pharmachological challenges. Conclusion: Our findings provide evidence that there are several changes in hormonal levels related to the functioning of the HPA axis and its receptors GR and MR in depressive patients associated to hypocortisolism and the increase of negative feedback MR- and GR- mediated. Our data also suggest the role of prolactin in the development of depressive disorder with ELS, however, more studies are needed to better highlight the importance of other hormones of HPA axis and its receptors in depressive disorders with ELS

O eixo hipotálamo-pituitária-adrenal é o principal sistema neuroendócrino envolvido na regulação e adaptação da resposta ao estresse e, o principal hormônio secretado é o cortisol. O cortisol exerce seus efeitos por meio dos receptores mineralocorticoide (MR) e glicocorticoide (GR). Variações nos genes desses receptores têm sido associadas à sensibilidade aos glicocorticoides e mudanças no perfil metabólico. O objetivo geral desse trabalho foi compreender a variabilidade existente em relação às respostas fisiológicas de bovinos por meio da identificação de polimorfismos genéticos em genes envolvidos na resposta ao estresse e, verificar as consequências dessa variação genética em características de qualidade da carne. Dessa forma, três abordagens foram propostas: (1) avaliar a incidência de carne DFD (dark, firm and dry) e seu impacto no perfil metabólico, endócrino e características de qualidade da carne bovina, uma vez que o estresse é um dos principais fatores que levam a essa condição desfavorável; (2) avaliar a contribuição de fatores genéticos, por meio da identificação de polimorfismos de nucleotídeo único (SNPs), no gene do MR e GR, e suas associações com as características mensuradas; (3) avaliar os efeitos desses polimorfismos sobre o perfil proteico do músculo bovino. Foram utilizados 241 bovinos da raça Nelore. Os resultados evidenciaram implicações direta do pH 24 horas post-mortem nos atributos de cor e perdas por cozimento da carne. A incidência de carnes DFD (pH>=5,8) foi de 18,7%. Os polimorfismos identificados mostraram influenciar em algumas características mensuradas. Os SNPs NR3C2_1 e NR3C2_2 no gene do MR foram associados ao conteúdo de glicogênio muscular e nível plasmático do hormônio adrenocorticotrófico (ACTH) post-mortem, e o SNP NR3C1_1 no gene do GR foi associado aos níveis plasmático de cortisol post-mortem. As análises proteômicas demonstraram que a maioria das proteínas reguladas por esses SNPs estão envolvidas na contração muscular, metabolismo e defesa celular. Portanto, é possível inferir que o pH tem impacto nas características de qualidade da carne e que polimorfismos em MR e o GR levam a mudanças na atividade do eixo HPA, no perfil metabólico do organismo e no perfil proteico do músculo, sugerindo que esses genes estão envolvidos em uma complexidade de funções e podendo ser alvos de estudos em sistemas de produção que visam melhorar a produtividade. / The hypothalamic-pituitary-adrenal axis is the main neuroendocrine system involved in the regulation and adaptation in stress response and the primary hormone secreted is cortisol. Cortisol exerts its effects through the mineralocorticoid (MR) and glucocorticoid (GR) receptors. Variations in the genes of these receptors have been associated with sensitivity to glucocorticoids and changes in the metabolic profile. The general objective of this work was to understand the variability in relation to physiological responses of cattle through identification of genetic polymorphisms in genes involved in stress response and, checking the consequences of this genetic variation in meat quality traits. Thus, three approaches have been proposed: (1) evaluate the incidence of DFD meat (dark, firm and dry) and its impact on metabolics, endocrines profiles and meat quality traits, since stress is the major factor that lead to this unfavorable condition; (2) evaluate the contribution of genetic factors through identification single nucleotide polymorphisms (SNPs) in the MR and GR gene and its association with the measured traits; (3) evaluate the effects of these polymorphisms on the protein profile of bovine muscle. A total of 241 Nellore cattle were used. The results evidenced direct implications of 24 hours pH post-mortem in color attributes and cooking losses. The incidence of DFD meat (pH >= 5.8) was 18.7%. The polymorphisms identified demonstrated to influence some on measured characteristics. The NR3C2_1 and NR3C2_2 SNPs in MR gene were associated with muscle glycogen content and post-mortem adrenocorticotropic hormone (ACTH) plasma levels and, the NR3C1_1 SNP in GR was associated with post-mortem cortisol plasma levels. The proteomic analysis demonstrated that most proteins regulated by these SNPs are involved in muscle contraction, metabolism and cellular defense. Therefore, it is possible to infer that pH has impact on meat quality traits and MR and GR polymorphisms lead to changes in the HPA axis activity, metabolic profile and protein muscle profile, suggesting that these genes are involved in a complexity of functions and may be targets for studies on production systems to improve productivity.